CDMO News
C3i Secures EMA Approval to Manufacture Cell Therapies for Europe
C3i has obtained regulatory approval from the European Medicines Agency (EMA) to manufacture cell therapies for the European market. The certification follows an inspection of the company’s Montreal facility, which confirmed compliance with Good Manufacturing Practice (GMP) standards. This approval enables C3i, a Canadian contract development and
20 February 2025